|
Outcomes
|
VRE screening and isolation
|
No VRE screening and isolation
|
Differencea (%)
|
|---|
|
Non-isolated cases
|
11/1000
|
60/1000
|
−49/1000 (82%)
|
|
Healthcare-associated VRE-colonisation
|
2/1000
|
8/1000
|
−6/1000 (73%)
|
|
Infected cases
|
5.7/1000
|
6.3/1000
|
−0.6/1000 (10%)
|
|
VRE-related bacteremia
|
2.6/1000
|
2.8/1000
|
−0.2/1000 (7%)
|
|
Other VRE infections (e.g. UTI)
|
3.2/1000
|
3.6/1000
|
−0.4/1000 (12%)
|
|
Deaths subsequent to VRE infection
|
0.5/1000
|
0.6/1000
|
−0.1/1000 (8%)
|
|
ICER ($/QALY)
| | |
7850
|
|
Total costs ($)
|
118.37
|
6.72
|
112
|
|
Total QALY gained
|
20.5607
|
20.5465
|
0.0142
|
- aDifference for health outcomes were calculated by subtracting “no VRE screening and isolation strategy” outcomes from “VRE screening and isolation strategy” outcomes. Percentage change was calculated relative to “no VRE screening and isolation strategy” outcomes
- ICER incremental cost-effectiveness ration, QALY quality-adjusted life years, UTI urinary tract infection, VRE vancomycin-resistant enterococci
